Home > Trending on TAP > April 2019 > Resveratrol in Post-Stroke Patients

Resveratrol in Post-Stroke Patients

4/16/2019 10:56:33 AM
During a stroke, reactive oxygen species are generated, which trigger inflammatory mediators, mitochondrial dysfunction, endothelial dysfunction, and neuronal death. Oxidative stress continues to play a role in ischemic brain injury following a cerebrovascular attack. Many of the parameters that serve as major risk factors for stroke (e.g., hypertension, hypercholesterolemia, obesity, and diabetes) are also mediated or exacerbated by oxidative stress. It has been suggested that stroke therapies should include modalities to mitigate the effects of reactive oxygen species over time.
Resveratrol is an antioxidant compound that is known to counteract oxidative stress and inflammation. A placebo-controlled trial of resveratrol investigated its effect in patients who had suffered a stroke within the last 12 months.

Resveratrol studied for control of metabolic parameters

A total of 228 post-stroke patients were randomized to one of 3 groups: the control group received conventional treatment and physical rehabilitation; the low-dose resveratrol group received the same as the control plus 100 mg of resveratrol per day; the high-dose resveratrol group received the same as the control plus 200 mg of resveratrol per day. Patients were monitored for blood pressure, weight, lipid profile, and glucose profile at 6 months and 12 months.
Resveratrol supplementation had a beneficial effect on all of the monitored parameters that serve as major risk factors for stroke. Significant improvements in blood pressure, body mass index, lipid profile, and glucose were observed in both the 100-mg and 200-mg resveratrol groups when compared with the control. The only significant difference between the different dosages of resveratrol was seen in triglyceride levels, where the higher dosage performed better. For all other parameters, the 100-mg-per-day dosage was statistically equivalent to the 200-mg dosage.

Reseveratrol lowers blood pressure, BMI, cholesterol, glucose

Examples of the magnitude of effect over 12 months on the monitored parameters follow. Low-dose resveratrol decreased systolic blood pressure from a mean of 148 mmHg to 143 mmHg, and high-dose resveratrol decreased it from 149 mmHg to 139 mmHg. The biggest decrease in BMI was observed in the high-dose resveratrol group (dropping from 29.50 kg/m2 to 25.77 kg/m2). For lipid parameters, the effect of low-dose resveratrol was 2 times greater than the control for HDL cholesterol and 2.34 times greater for LDL cholesterol. Resveratrol decreased blood glucose levels significantly in both diabetic and nondiabetic patients.   
The evidence from this clinical trial supports a role for resveratrol supplementation as an adjuvant therapy to improve risk factor parameters in post-stroke patients.
Fodor K, Tit DM, Pasca B et al. Long-Term Resveratrol Supplementation as a Secondary Prophylaxis for Stroke. Oxidative Medicine and Cellular Longevity. 2018.

Have Clinical Research Summaries Delivered to Your Inbox
TAP Integrative is your go-to resource for integrative clinical protocols, case studies, and evidence-based clinical information. Sign up for TAP’s enewsletter and receive integrative clinical research summaries, clinical pearls and tips from integrative experts delivered straight to your inbox. Bonus: Receive TAP’s top 3 patient education downloads FREE. Subscribe here >>>